Agios Pharmaceuticals
AGIO· Manufacturing· Fiscal year ends in December
Brian Goff is the CEO of Agios Pharmaceuticals and was paid $5.4M in FY2025 (Dec), down 21%.
Executives5
See all- 1Brian GoffChief Executive OfficerFY2025
- 2Krishnan Viswanadhan, Pharm.DChief Corporate Development & Strategy OfficerFY2025
- 3Cecilia JonesChief Financial OfficerFY2025
- 4James BurnsChief Legal OfficerFY2025
- 5Sarah GheuensChief Medical Officer, Head of Research & DevelopmentFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAgios Pharmaceuticals paid its 5 named executives $15.1M in total in FY2025 (Dec). CEO Brian Goff was paid $5.4M of that.
| Name | |||
|---|---|---|---|
| Brian GoffChief Executive Officer | |||
| Krishnan Viswanadhan, Pharm.DChief Corporate Development & Strategy Officer | |||
| Cecilia JonesChief Financial Officer | |||
| James BurnsChief Legal Officer | |||
| Sarah GheuensChief Medical Officer, Head of Research & Development |
of each named executive, from the Summary Compensation Table of each proxy.
Peers14
See allThe FY2025 (Dec) proxy of Agios Pharmaceuticals names 14 peer companies for pay. Among Agios Pharmaceuticals and these peers, CEO pay was the lowest of 3 and total shareholder return was 2nd highest of 3.
3rd highest of 3in Agios Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
2nd highest of 3in Agios Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Feb 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Feb 13, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 15, 2024 | FY2023 |
